Predictive efficacy of serum hepcidin, ferritin, and q-Dioxn MRI for upgrading, upstaging, and biochemical recurrence in prostate cancer patients: A comparative study.
- Author:
Zhen TIAN
1
;
Guang-Zheng LI
2
;
Ren-Peng HUANG
3
;
Si-Yu WANG
1
;
Li-Chen JIN
1
;
Yu-Xin LIN
1
;
Yu-Hua HUANG
1
Author Information
1. Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China.
2. Department of Radiology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China.
3. Department of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China.
- Publication Type:English Abstract
- Keywords:
prostate cancer;
hepcidin;
ferritin;
upgrading;
upstaging;
biochemical recurrence
- MeSH:
Humans;
Male;
Prostatic Neoplasms/diagnosis*;
Hepcidins/blood*;
Ferritins/blood*;
Middle Aged;
Magnetic Resonance Imaging/methods*;
Aged;
Neoplasm Recurrence, Local;
Neoplasm Staging
- From:
National Journal of Andrology
2025;31(9):800-806
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:The aim of this study is to explore the correlation among serum hepcidin, ferritin, and q-Dioxn MRI with upgrading, upstaging and biochemical recurrence in prostate cancer (PCa) patients.
METHODS:A total of 103 PCa patients diagnosed by biopsy were selected for this study. All patients underwent q-Dixon MRI prior to biopsy for T2* value measurement. Then serum hepcidin and ferritin were measured before receiving radical prostatectomy. Pathological grading and staging were conducted both preoperatively and postoperatively. The correlations among hepcidin, ferritin, T2* values, and postoperative upgrading, upstaging, biochemical recurrence were subsequently analyzed.
RESULTS:The hepcidin level of PCa patients was measured at (123.51 ± 23.03) ng/mL, while the ferritin level was recorded at (239.80 ± 79.59) ng/mL, and the T2* value was (41.07 ± 6.37) ms. A total of 49 and 36 cases were observed with upgrading and upstaging in postoperative pathology, respectively. The median follow-up duration was 28.0 months (6.0－38.0 months), during which biochemical recurrence was observed in 12 cases. For upgrading, hepcidin and ferritin demonstrated the predictive efficacy, with areas under the ROC curve of 0.777 and 0.642, respectively, whereas T2* values did not show sufficient predictive power. For upstaging, hepcidin, ferritin, and T2* exhibited predictive efficacy, with areas under the ROC curve of 0.806, 0.696, and 0.655, respectively. Multivariate Logistic regression analysis indicated that hepcidin served as an independent risk factor for both upgrading (OR 1.055, 95%CI 1.027－1.085, P<0.001) and upstaging (OR 1.094, 95%CI 1.040－1.152, P<0.001). Cox regression analysis showed that hepcidin (95%CI 1.000－1.052, P = 0.049) was a significant risk factor for predicting biochemical recurrence.
CONCLUSION:Hepcidin could serve as a predictor for pathological upgrading, upstaging and biochemical recurrence after radical prostatectomy, which provides a novel potential index for risk stratification and prognostic evaluation of PCa patients.
